Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00579514 · ClinicalTrials.gov registry record · NA

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

A NA study of Breast Cancer and Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
21,081
Enrollment target
1
Study location

NCT00579514 is a NA study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21,081 participants, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (657% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00579514, a NA study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
21,081 participants
Enrollment target
1
Study location

Study Summary

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

Interventions

  • GENETIC PCR/PCR/LDR Strategy

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 21,081 participants
Start Date 2000-03
Est. Completion 2026-03
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT00579514

The ClinicalTrials.gov registry entry for NCT00579514 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 21,081 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (657% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PCR/PCR/LDR Strategy is the first listed.

NCT00579514 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00579514 about?

NCT00579514 is a clinical study titled "Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients". The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to gen...

What is the current status of trial NCT00579514?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 21,081 participants. The study started on 2000-03. Estimated completion is 2026-03.

What conditions does trial NCT00579514 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Bladder Cancer.

What interventions are being tested in trial NCT00579514?

The interventions under investigation include: PCR/PCR/LDR Strategy (GENETIC).

Who is sponsoring clinical trial NCT00579514?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00579514 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.